Corpus overview


Overview

MeSH Disease

Pneumonia (938)

Infections (439)

Disease (435)

Coronavirus Infections (273)

Death (203)


Human Phenotype

Pneumonia (1024)

Fever (166)

Cough (133)

Respiratory distress (78)

Hypertension (59)


Transmission

Seroprevalence
    displaying 41 - 50 records in total 1064
    records per page




    Integrative Analysis for COVID-19 Patient Outcome Prediction

    Authors: Hanqing Chao; Xi Fang; Jiajin Zhang; Fatemeh Homayounieh; Chiara D. Arru; Subba R. Digumarthy; Rosa Babaei; Hadi K. Mobin; Iman Mohseni; Luca Saba; Alessandro Carriero; Zeno Falaschi; Alessio Pasche; Ge Wang; Mannudeep K. Kalra; Pingkun Yan

    id:2007.10416v1 Date: 2020-07-20 Source: arXiv

    While image analysis of chest computed tomography (CT) for COVID-19 diagnosis has been intensively studied, little work has been performed for image-based patient outcome prediction. Management of high-risk patients with early intervention is a key to lower the fatality rate of COVID-19 pneumonia MESHD pneumonia HP, as a majority of patients recover naturally. Therefore, an accurate prediction of disease progression MESHD with baseline imaging at the time of the initial presentation can help in patient management. In lieu of only size and volume information of pulmonary abnormalities and features through deep learning based image segmentation, here we combine radiomics of lung opacities and non-imaging features from demographic data, vital signs, and laboratory findings to predict need for intensive care unit (ICU) admission. To our knowledge, this is the first study that uses holistic information of a patient including both imaging and non-imaging data for outcome prediction. The proposed methods were thoroughly evaluated on datasets separately collected from three hospitals, one in the United States, one in Iran, and another in Italy, with a total 295 patients with reverse transcription polymerase chain reaction (RT-PCR) assay positive COVID-19 pneumonia MESHD pneumonia HP. Our experimental results demonstrate that adding non-imaging features can significantly improve the performance SERO of prediction to achieve AUC up to 0.884 and sensitivity SERO as high as 96.1%, which can be valuable to provide clinical decision support in managing COVID-19 patients. Our methods may also be applied to other lung diseases MESHD including but not limited to community acquired pneumonia MESHD pneumonia HP.

    The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models

    Authors: Kim M Stegmann; Antje Dickmanns; Sabrina Gerber; Vella Nikolova; Luisa Klemke; Valentina Manzini; Denise Schloesser; Cathrin Bierwirth; Julia Freund; Maren Sitte; Raimond Lugert; Gabriela Salinas; Dirk Goerlich; Bernd Wollnik; Uwe Gross; Matthias Dobbelstein

    doi:10.1101/2020.07.18.210013 Date: 2020-07-20 Source: bioRxiv

    The search for successful therapies of infections MESHD with the coronavirus SARS-CoV-2 is ongoing. We tested inhibition of host cell nucleotide synthesis as a promising strategy to decrease the replication of SARS-CoV-2-RNA, thus diminishing the formation of virus progeny. Methotrexate (MTX) is an established drug for cancer therapy and to induce immunosuppression. The drug inhibits dihydrofolate reductase and other enzymes required for the synthesis of nucleotides. Strikingly, the replication of SARS-CoV-2 was inhibited by MTX in therapeutic concentrations around 1 M, leading to more than 1000-fold reductions in virus progeny in Vero C1008 (Vero E6) as well as Calu-3 cells. Virus replication was more sensitive to equivalent concentrations of MTX than of the established antiviral agent remdesivir. MTX strongly diminished the synthesis of viral structural proteins and the amount of released virus RNA. Virus replication and protein synthesis were rescued by folinic acid (leucovorin) and also by inosine, indicating that purine depletion is the principal mechanism that allows MTX to reduce virus RNA synthesis. The combination of MTX with remdesivir led to synergistic impairment of virus replication, even at 300 nM MTX. The use of MTX in treating SARS-CoV-2 infections MESHD still awaits further evaluation regarding toxicity and efficacy in infected organisms, rather than cultured cells. Within the frame of these caveats, however, our results raise the perspective of a two-fold benefit from repurposing MTX for treating COVID-19. Firstly, its previously known ability to reduce aberrant inflammatory responses might dampen respiratory distress HP. In addition, its direct antiviral activity described here would limit the dissemination of the virus. SIGNIFICANCEO_LIMTX is one of the earliest cancer drugs to be developed, giving rise to seven decades of clinical experience. It is on the World Health Organizations List of Essential Medicines, can be administered orally or parenterally, and its costs are at single digit {euro} or $ amounts/day for standard treatment. In case of its successful further preclinical evaluation for treating SARS-CoV-2 infections MESHD, its repurposing to treat COVID-19 would thus be feasible, especially under low-resource conditions. C_LIO_LIAdditional drugs exist to interfere with the synthesis of nucleotides, e.g. additional folate antagonists, inhibitors of GMP synthetase, or inhibitors of dihydroorotate dehydrogenase (DHODH). Such inhibitors have been approved as drugs for different purposes and might represent further therapeutic options against infections MESHD with SARS-CoV-2 C_LIO_LIRemdesivir is currently the most established drug for treating COVID-19. Our results argue that MTX and remdesivir, even at moderate concentrations, can act in a synergistic fashion to repress virus replication to a considerably greater extent than either drug alone. C_LIO_LICOVID-19, in its severe forms, is characterized by pneumonia MESHD pneumonia HP and acute respiratory distress HP syndrome MESHD, and additional organ involvements. These manifestations are not necessarily a direct consequence of virus replication and cytopathic effects, but rather a result of an uncontrolled inflammatory and immune response. Anti-inflammatory drugs such as glucocorticoids are thus being evaluated for treating COVID-19. However, this bears the risk of re-activating virus spread by suppressing a sufficient and specific immune response. In this situation, it is tempting to speculate that MTX might suppress both excessive inflammation MESHD as well as virus replication at the same time, thus limiting both the pathogenesis of pneumonia MESHD pneumonia HP and also the spread of virus within a patient. C_LI

    Clinical characteristics and risk factors for mortality in patients with coronavirus disease MESHD 2019 in intensive care unit: a single-center, retrospective, observational study in China

    Authors: Fangfang Sai; Xiaolei Liu; Lanyu Li; Yan Ye; Changqing Zhu; Ying Hang; Conghua Huang; Lei Tian; Xinhui Xu; Huan Huang

    doi:10.21203/rs.3.rs-46078/v1 Date: 2020-07-20 Source: ResearchSquare

    Background: Coronavirus disease MESHD 2019 (COVID-19) is a potentially life-threatening contagious disease MESHD disease which has spread TRANS which has spread all over the world. Risk factors for the clinical outcomes of COVID-19 pneumonia MESHD pneumonia HP in intensive care unit (ICU) have not yet been well determined. Methods: In this retrospective, single-centered, observational study, we consecutively included 47 patients with confirmed COVID-19 who were admitted to the ICU of Leishenshan Hospital in Wuhan, China, from February 24 to April 5, 2020. Clinical characteristics and outcomes were collected and compared between survivors and non-survivors. Multivariable logistic regression was used to explore the risk factors associated with death MESHD in patients of COVID-19.Results: The study cohort included 47 adult TRANS patients with a median age TRANS of 70.55±12.52 years, and 30 (63.8%) patients were men. Totally 15 (31.9%) patients died. Compared with survivors, non-survivors were more likely to develop septic shock MESHD shock HP (6 [40%] patients vs 3 [9.4%] patients ), disseminated intravascular coagulation MESHD disseminated intravascular coagulation HP (3 [21.4%] vs 0), and had higher score of APACHE II (25.07±8.03 vs 15.56±5.95), CURB-65 (3[2-4] vs 2[1-3]), Sequential Organ Failure Assessment (SOFA) (7[5-9] vs 3[1-6]), higher level of D-dimer (5.74 [2.32-18] vs 2.05 [1.09-4.00] ) and neutrophil count (9.4[7.68-14.54] vs 5.32[3.85-9.34] ). SOFA score (OR 1.47, 1.01–2.13; p=0.0042) and lymphocyte count (OR 0.02, 0.00–0.86; p=0.042) on admission were independently risk factors for mortality. Patients with higher lymphocyte count (>0.63×109/L) and lower SOFA score ≤4 on admission had a significantly well prognosis than those with lower lymphocyte count (≤0.63×109/L) and higher SOFA score >4 in overall survival.Conclusions: Higher SOFA score and lower lymphocyte count on admission were associated with poor prognosis of patients with COVID-19 in ICU. Lymphocyte count may serve as a promising prognostic biomarker.

    Starting from the Influence of Tobacco: AKR1C3 and COVID-19 Receptor ACE2 Are Potential Pprognostic Biomarkers for Brain Lower Grade Glioma MESHD Glioma HP, Evidence from Bioinformatics Analyses

    Authors: Heng-Yi Yang; Tian-Ni Mao

    id:10.20944/preprints202007.0411.v1 Date: 2020-07-19 Source: Preprints.org

    Background: Coronavirus disease MESHD (COVID-19) related pneumonia MESHD pneumonia HP is leaded by Severe Acute Respiratory Syndrome MESHD Coronavirus 2 (SARS-CoV-2), which infects host cells through receptors named Angiotensin-converting enzyme 2 (ACE2). Smoking is thought to be related to poor disease MESHD prognosis, as a large amount of evidence highlights the negative effects of smoking on lung health and its causal relationship with various respiratory diseases MESHD. Methods: We first evaluated the role of ACE2 expression level with tobacco effect. And correlation analyses were used to identify the related genes of ACE2 both in smoker trait and human normal multi-tissues. After intersections, hub genes were later used to further GSEA and co-regulated mechanisms were explored by GeneMANIA. We used UALCAN to perform survival curves of pan-cancers included 33 types of cancers. New clinical model of top co-occurrence cancer type was constructed and validated. Results: Effected by cigarette smoking, the expression level of ACE2 expressed statistically upwards in current smokers compared with never smokers, upwards in groups after acute smoke exposed compared with normal control. But no strong evidence detected in third-hand smoke, as poor amounts of samples, only 4. A little trend of expressing upwards became in groups after third-hand smoke compared with groups after clean air exposing. 4 genes included PIR, ADH7, AKR1C2 and AKR1C3 were identified as ACE2 related genes in smoker trait and human normal multi-tissues. Then, we made the survival curves of pan-cancers in 4 genes. Brain lower grade glioma MESHD glioma HP was the co-occurrence type as both ACE2, PIR and AKR1C3 had the significantly prognostic situation. Later, we made the new clinical prediction model as the C-index was 0.827 and the Area Under Curves (AUCs) of 1-year survival, 2-year survival and 3-year survival were 0.921(95%CI, 0.882-0.961), 0.911(95%CI, 0.860-0.962) and 0.878(95%CI, 0.818-0.939). In inner validation, the AUCs of 1-year survival, 2-year survival and 3-year survival were 0.777(95%CI, 0.640-0.914), 0.916(95%CI, 0.842-0.990) and 0.888(95%CI, 0.768-1.000). In outer validation one, the AUCs of 1-year survival, 2-year survival and 3-year survival were 0.764(95%CI, 0.672-0.856), 0.848(95%CI, 0.783-0.913) and 0.748(95%CI, 0.656-0.841). And in outer validation two the AUCs of 1-year survival, 2-year survival and 3-year survival were 0.740(95%CI, 0.654-0.826), 0.766(95%CI, 0.688-0.843) and 0.794(95%CI, 0.721-0.866). Conclusions: In our study, we compared the ACE2 expression level between smokers and non-smokers crowds and identified associated hub genes. Then we explored the further role of hub genes in tumor fields to identify the correlation and influence between the avoidable host factors such as smoking on COVID-19 contamination and tumor. ACE2 and AKR1C3 are potential prognostic genes for brain lower grade glioma MESHD glioma HP, and we created the web dynamic nomogram and encapsulation app through validations.

    Can Adenosine Fight COVID-19 Acute Respiratory Distress HP Syndrome MESHD?

    Authors: Carmela Falcone; Massimo Caracciolo; Pierpaolo Correale; Sebastiano Macheda; Eugenio Giuseppe Vadalà; Stefano La Scala; Marco Tescione; Roberta Danieli; Anna Ferrarelli; Maria Grazia Tarsitano; Lorenzo Romano; Antonino De Lorenzo

    id:10.20944/preprints202007.0426.v1 Date: 2020-07-19 Source: Preprints.org

    Some COVID-19 patients develop interstitial pneumonia MESHD pneumonia HP that can evolve into Acute Respiratory Distress HP Syndrome MESHD (ARDS). This is accompanied by an inflammatory cytokine storm. SarS-CoV has proteins capable of promoting cytokine storm, especially in patients with comorbidities, including obesity MESHD obesity HP. Since there is currently no resolutive therapy for ARDS and given the scientific literature regarding the use of adenosine, its application has been hypothesized. Adenosine through its receptors is able to inhibit the acute inflammatory process, increase the protection capacity of the epithelial barrier and reduce the damage due to an overactivation of the immune system, such as in cytokine storms. These features are known in ischemia MESHD / reperfusion models and could also be exploited in acute lung injury MESHD, with hypoxia MESHD. In light of these hypotheses, for compassionate use, a COVID-19 patient, with unresponsive respiratory failure HP, was treated with adenosine. The results showed a rapid and clear improvement in clinical conditions, with the negative effect of detection of SarS-CoV2.

    Clinical Severity and CT Features of the COVID-19 Pneumonia MESHD Pneumonia HP: Focus on CT Score and Laboratory Parameters

    Authors: Jianghui Duan; Kunsong Su; Hongliang Sun; Yanyan Xu; Liangying Liu

    doi:10.21203/rs.3.rs-45453/v1 Date: 2020-07-18 Source: ResearchSquare

    Background: Although CT characteristics of Coronavirus Disease MESHD 2019 (COVID-19) pneumonia MESHD pneumonia HP between patients with mild and severe forms of the disease MESHD have already been reported in the literature, there was little attention to the correlation of imaging features and laboratory testing. We aimed to compare the laboratory and chest CT imaging features in patients with COVID-19 pneumonia MESHD pneumonia HP between non-severe cases and severe cases, and to analyze the correlation of CT score and laboratory testing.Methods: This study consecutively included 54 patients with COVID-19 pneumonia MESHD pneumonia HP (26 males TRANS and 28 females TRANS, 26 to 92 years of age TRANS, 43 cases with non-severe and 11 cases with severe group). Clinical, laboratory and image data were collected between two subgroups. A CT score system was used to evaluate the extent of disease MESHD. Correlation between the CT score and laboratory data were estimated. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance SERO of CT score and laboratory tests.Results: Compared with non-severe patients, severe patients had showed increased white blood SERO cell count, neutrophil count, neutrophil percentage, the neutrophil-to-lymphocyte ratio (NLR) and decreased lymphocyte percentage (all p < 0.05). Architectural distortion, pleural effusion MESHD pleural effusion HP, air bronchogram and consolidation-dominant pattern were more common in the severe group (all p < 0.05). CT score of the severe group was higher than the non-severe group (p < 0.001). For distribution characters of the lesions, diffuse pattern in the transverse distribution was more often seen in the severe group (p < 0.001). CT score was positively correlated with the white blood SERO cell counts, neutrophil counts, the percent of neutrophil, NLR, alanine aminotransferase, lactate dehydrogenase and C-reactive protein, and was inversely related to the lymphocyte, the percent of lymphocyte. ROC analysis showed that when the optimal threshold of CT score was 13, the area under the curve was the largest, which was 0.855, and the sensitivity SERO and specificity were 100% and 60% respectively for the diagnosis of the severe patients.Conclusion: CT score showed significant correlations with laboratory inflammatory markers, suggesting that chest CT and laboratory examination maybe provide a better reference for clinicians to judge the severity of diseases MESHD.

    Cutaneous manifestations associated with COVID-19 in children TRANS: A Systematic Review

    Authors: Seema Shah; Kiran Akhade; Satyaki Ganguly; Rachita Nanda; Eli Mohapatra; Anil Kumar Goel

    doi:10.21203/rs.3.rs-45314/v1 Date: 2020-07-18 Source: ResearchSquare

    Background: Cutaneous manifestation of COVID 19 in children TRANS has not yet been reviewed systematically and hence this review gives a future direction to the clinicians to be vigilant for skin presentations during such pandemic.Methodology: The review was done as per the guidelines of PRISMA and literature search was done on PubMed database using keywords as COVID-19, children TRANS and skin in different combinations. Articles published in English with cases of age TRANS 1 month to 18 years were eligible. The outcome included varied aspects of cutaneous and COVID-19 infection MESHD. The review protocol was not registered.Results: Of 51 publications identified, 13 studies containing 149 children TRANS met the eligibility criteria. Acrally located erythematous maculopapular lesion was the most common finding in 138 children TRANS. Erythema multiforme MESHD Erythema HP, varicella like exanthem and Kawasaki disease MESHD like presentations were reported in the rest of the cases. The duration of the skin lesion was 1-2 weeks in 43%. Skin biopsy done in 18 cases revealed superficial & deep perivascular and peri-eccrine lymphocytic infiltrate & lymphocytic vasculitis MESHD vasculitis HP. RT-PCR was positive in 13.8% cases. Serological markers for HSV, parvovirus B19 analyzed across various studies, were found negative, except for mycoplasma pneumoniae MESHD pneumoniae HP in 2 of 20 cases tested.Discussion: Clinicopathologic analysis established chilblains MESHD chilblains HP like lesion in 43% cases with no confirmed TRANS etiology like cold exposure, autoimmune dysfunction, drug reaction, or viral infection MESHD. The usual cephalo-caudal spread of a viral exanthem was also missing. However, a low number of discussed cases was a limitation of the study.Conclusion: In the absence of any confirmed etiology for such cutaneous manifestations, the possibility of COVID-19 should be explored and evaluated thoroughly during such pandemic.

    Lung ultrasound and computed tomography to monitor COVID-19 pneumonia MESHD pneumonia HP in critically ill patients: a two-center prospective cohort study

    Authors: Micah Heldeweg; Jorge A. Lopez Matta; Mark E. Haaksma; Jasper M. Smit; Carlos V. Elzo Kraemer; Harm-Jan S. de Grooth; E. de Jonge; L.J. Meijboom; Leo M.A. Heunks; David J. van Westerloo; Pieter Roel Tuinman

    doi:10.21203/rs.3.rs-44726/v1 Date: 2020-07-17 Source: ResearchSquare

    Background: Lung ultrasound can adequately monitor disease MESHD severity in pneumonia MESHD pneumonia HP and acute respiratory distress HP syndrome MESHD. We hypothesize lung ultrasound can adequately monitor COVID-19 pneumonia MESHD pneumonia HP in critically ill patients. Methods: Adult TRANS patients with COVID-19 pneumonia MESHD pneumonia HP admitted to the intensive care unit of two academic hospitals who underwent a 12-zone lung ultrasound and a chest CT examination were included. Baseline characteristics, and outcomes including composite endpoint death MESHD or ICU stay >30 days were recorded. Lung ultrasound and CT images were quantified as a Lung Ultrasound Score Involvement index (LUSI) and CT Severity Involvement index (CTSI). Primary outcome was the correlation, agreement, and concordance between LUSI and CTSI. Secondary outcome was the association of LUSI and CTSI with the composite endpoints.Results: We included 55 ultrasound examinations in 34 patients, which were 88% were male TRANS, with a mean age TRANS of 63 years and mean P/F ratio of 151. The correlation between LUSI and CTSI was strong (r=0.795), with an overall 15% bias, and limits of agreement ranging -40 to 9.7. Concordance between changes in sequentially measured LUSI and CTSI was 81%. In the univariate model, high involvement on LUSI and CTSI were associated with a composite endpoint. In the multivariate model, LUSI was the only remaining independent predictor.Conclusions: Lung ultrasound can be used as an alternative for chest CT in monitoring COVID-19 pneumonia MESHD pneumonia HP in critically ill patients as it can quantify pulmonary involvement, register changes over the course of the disease MESHD, and predict death MESHD or ICU stay >30 days.Trial registration: NTR, NL8584. registered 01 May 2020 - retrospectively registered, https://www.trialregister.nl/trial/8584

    IgG antibody SERO seroconversion and the clinical progression of COVID-19 pneumonia MESHD pneumonia HP: A retrospective, cohort study

    Authors: Kazuyoshi Kurashima; Naho Kagiyama; Takashi Ishiguro; Yotaro Takaku; Hiromi Nakajima; Shun Shibata; Yuma Matsui; Kenji Takano; Taisuke Isono; Takashi Nishida; Eriko Kawate; Chiaki Hosoda; Yoichi Kobayashi; Noboru Takayanagi; Tsutomu Yanagisawa

    doi:10.1101/2020.07.16.20154088 Date: 2020-07-17 Source: medRxiv

    Background: Coronavirus Disease MESHD 2019 (COVID-19) causes severe acute respiratory failure HP. Antibody SERO-dependent enhancement (ADE) is known as the mechanism for severe forms of other coronavirus diseases MESHD. The clinical progression of COVID-19 before and after IgG antibody SERO seroconversion was investigated. Methods: Fifty-three patients with reverse transcriptase PCR (RT-PCT)-confirmed COVID-19 viral pneumonia MESHD pneumonia HP with or without respiratory failure HP were retrospectively investigated. The timing of the first IgG antibody SERO against SARS-CoV-2-positive date, as well as changes of C-reactive protein (CRP) as an inflammatory marker and blood SERO lymphocyte numbers, was assessed using serial preserved blood SERO samples. Findings: Ten patients recovered without oxygen therapy (mild/moderate group), 32 patients had hypoxemia HP and recovered with antiviral drugs (severe/non-ICU group), and 11 patients had severe respiratory failure HP and were treated in the ICU (6 of them died; critical/ICU group). The first IgG-positive date (day 0) was observed from 5 to 18 days from the onset of disease MESHD. At day 0, a CRP peak was observed in the severe and critical groups, whereas there was no synchronized CRP peak on day 0 in the mild/moderate group. In the severe/non-ICU group, the blood SERO lymphocyte number increased (P=0.0007) and CRP decreased (P=0.0007) after day 0, whereas CRP did not decrease and the blood SERO lymphocyte number further decreased (P=0.0370) in the critical/ICU group. Interpretation: The respiratory failure HP due to COVID-19 viral pneumonia MESHD pneumonia HP observed in week 2 may be related to an antibody SERO-related mechanism rather than uncontrolled viral replication. In the critical form of COVID-19, inflammation MESHD was sustained after IgG seroconversion.

    Clinical Characteristics of 2019 Novel Coronavirus Pneumonia MESHD Pneumonia HP in China: A Systematic Review and Meta-analysis

    Authors: Kai Qian; Guo-Ping Wang; Hao Peng; Jun Peng; Hong-Zhong Cheng; Yi Deng; Jun Liu

    doi:10.21203/rs.3.rs-44722/v1 Date: 2020-07-17 Source: ResearchSquare

    Background Although novel pneumonia MESHD pneumonia HP associated with the Corona Virus Disease MESHD 2019 (COVID-19) suddenly broke out in China, China has controlled this epidemic effectively. Therefore, evidence-based descriptions of medical and clinical characteristics in China are necessary.Methods Literatures have been systematically performed a search on PubMed, Embase, Web of Science, GreyNet International, and The Cochrane Library from inception up to March 15, 2020. Quality of evidence was evaluated according to the STROBE checklist, and publication bias was analyzed by Egger’s test. In the single-arm meta-analysis, A random-effects model was used to obtain a pooled incidence rate. We conducted subgroup analysis according to geographic region and research scale.Results A total of 30 Chinese studies and 1969 patients were included in this meta-analysis. The valid pooled incidence rates of symptoms were as follows: rhinorrhea HP 5.1% (95% CI: 3.7–6.8, I2 = 31.90), diarrhea MESHD diarrhea HP 11.0% (95% CI: 9.3–12.9, I2 = 16.58), pharyngalgia 9.4% (95% CI: 7.5–11.7, I2 = 36.40), headache MESHD headache HP 9.5% (95% CI: 8.5–11.1, I2 = 5.7), and lymphocytopenia 36.7% (95% CI: 33.8–39.8 I2 = 28.73). Meanwhile, 4.3% (95% CI: 3.5–5.4, I2 = 0.00) of patients were found without any symptoms, although they were diagnosed by RT-PCR. In terms of lung CT imaging, most of the patients showed bilateral mottling or ground-glass opacity, and 7.7% (95% CI: 4.4–12.9, I2 = 35.64) of patients had a crazy-paving pattern. In subgroup analysis, the pooled incidence rate of normal CT presentations in the Wuhan area and outside Wuhan area was 2.3% (95% CI: 1.4–3.6, I2 = 24.78) and 5.8% (95% CI: 4.4–7.7, I2 = 32.76) respectively (P = 0.001).Conclusions The findings suggest that although most of the COVID-19 patients have symptoms or abnormal CT imaging presentations, a few of them accompany with no symptoms or abnormal CT imaging results should also be noticed. The digestive symptoms and lymphocytopenia may be the potential clinical characteristics, especially for patients with a history of contact with COVID-19. Additionally, the incidence rate of ARDS in the Wuhan area and outside Wuhan area was different; however, the reasons for this phenomenon are unclear.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.